Study wrapper · #1173
Tirzepatide Use Is Associated with Reduced Risk of Carpal Tunnel Syndrome in Overweight and Obese Adults.
Editor's note
An unexpected corner of the tirzepatide story: carpal tunnel syndrome is linked to obesity and diabetes, so a drug that improves both could plausibly lower risk. The target-trial-emulation design and extensive sensitivity analyses are stronger than typical database work, but this remains retrospective claims-style data, where diagnosis capture and residual confounding can move hazard ratios of this size. The 0.82 hazard ratio against other GLP-1 agents is modest; the comparison against non-incretin drugs is the more convincing signal.
Plain-language abstract
Using a large US health-records network, researchers found that overweight and obese adults who started tirzepatide had a lower rate of new carpal tunnel syndrome than similar patients on GLP-1 drugs (18% lower) or other weight-loss medications (25% lower). The authors read the results as pointing to possible metabolic and nerve-related benefits.